In Vitro Evaluation of No-Carrier-Added Radiolabeled Cisplatin ([189, 191Pt]cisplatin) Emitting Auger Electrons

Due to their short-range (2-500 nm), Auger electrons (Auger e(-)) have the potential to induce nano-scale physiochemical damage to biomolecules. Although DNA is the primary target of Auger e(-), it remains challenging to maximize the interaction between Auger e(-) and DNA. To assess the DNA-damaging effect of Auger e(-) released as close as possible to DNA without chemical damage, we radio-synthesized no-carrier-added (n.c.a.) [Pt-189,Pt- 191]cisplatin and evaluated both its in vitro properties and DNA-damaging effect. Cellular uptake, intracellular distribution, and DNA binding were investigated, and DNA double-strand breaks (DSBs) were evaluated by immunofluorescence staining of gamma H2AX and gel electrophoresis of plasmid DNA. Approximately 20% of intracellular radio-Pt was in a nucleus, and about 2% of intra-nucleus radio-Pt bound to DNA, although uptake of n.c.a. radio-cisplatin was low (0.6% incubated dose after 25-h incubation), resulting in the frequency of cells with gamma H2AX foci was low (1%). Nevertheless, some cells treated with radio-cisplatin had gamma H2AX aggregates unlike non-radioactive cisplatin. These findings suggest n.c.a. radio-cisplatin binding to DNA causes severe DSBs by the release of Auger e(-) very close to DNA without chemical damage by carriers. Efficient radio-drug delivery to DNA is necessary for successful clinical application of Auger e(-).

Automated summary

Research has shown that the use of no-carrier-added radio-cisplatin can cause severe DNA damage without chemical harm, by releasing Auger electrons very close to the DNA target. Although uptake is low, this method can still induce DNA double-strand breaks effectively. Efficient delivery of radio-drugs to DNA is crucial for the successful clinical application of Auger electrons.